The field of genetics is rapidly evolving and new medical breakthroughs are occuring as a result of advances in knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines.
- Five sections on the latest advances in complex traits
- Methods for testing with ethical, legal, and social implications
- Hot topics include discussions on systems biology approach to drug discovery; using comparative genomics for detecting human disease genes; computationally intensive challenges, and more
Inhaltsverzeichnis
1;Cover;1 2;Contents;6 3;Contributors;16 4;Preface to First Edition;22 5;Preface to Second Edition;26 6;Acknowledgments;28 7;Part I: Overview and Fundamentals;29 7.1;Chapter 1: An Overview of the Genetic Dissection of Complex Traits;31 7.1.1;I. Introduction;32 7.1.2;II. Challenges Arising From Complex Traits;35 7.1.3;III. Study Design;37 7.1.3.1;A. Phenotype;37 7.1.3.2;B. Genotype;38 7.1.3.3;C. Linkage versus association;38 7.1.3.4;D. Sampling type;39 7.1.3.5;E. Sample size, significance level, and power;39 7.1.4;IV. Analytical Methods;40 7.1.4.1;A. Familial aggregation and genetic effects;41 7.1.4.2;B. Linkage, association, and admixture mapping;41 7.1.4.3;C. Dense SNPs and haplotype analysis;44 7.1.4.4;D. Composite likelihoods;46 7.1.4.5;E. Multiple testing;46 7.1.5;V. Special Topics;47 7.1.5.1;A. Pathway-based association studies and Bayesian networks;47 7.1.5.2;B. Gene expression and systems biology;48 7.1.5.3;C. Comparative genomics;49 7.1.6;VI. GWA Studies;50 7.1.6.1;A. Recent GWA studies;50 7.1.6.2;B. Designing GWA studies;51 7.1.6.3;C. On transferability of genome-wide tagSNPs;52 7.1.6.4;D. Follow-up studies;53 7.1.7;VII. Efficient Strategies for Enhancing Gene Discovery;53 7.1.7.1;A. Lumping and splitting;53 7.1.7.2;B. Meta-analysis;55 7.1.7.3;C. Multivariate phenotypes;56 7.1.8;VIII. Discussion;56 7.1.9;Acknowledgments;57 7.1.10;References;58 7.2;Chapter 2: Familial Resemblance and Heritability;63 7.2.1;I. Introduction;64 7.2.2;II. Familial Resemblance and Heritability;66 7.2.2.1;A. Family resemblance;66 7.2.2.2;B. Heritability;66 7.2.2.3;C. Risk-based estimates of heritability;67 7.2.3;III. Study Designs and Multifactorial Models;69 7.2.3.1;A. Nuclear families;69 7.2.3.2;B. Extended pedigrees;71 7.2.3.3;C. Twins;71 7.2.3.4;D. Adoptions;71 7.2.3.5;E. Modeling extensions;72 7.2.3.6;F. Factors affecting heritability estimation;73 7.2.4;IV. Discussion;74 7.2.5;Acknowledgments;75 7.2.6;References;75 7.3;Chapter 3: Linkage and Association: Basic Concepts;79 7.3
.1;I. Introduction;80 7.3.2;II. Historical Perspective;82 7.3.3;III. Fundamentals and Methods;83 7.3.3.1;A. Linkage analysis;83 7.3.3.2;B. Association analysis;87 7.3.4;IV. Seven Stages of Relationship With GW Studies;92 7.3.5;V. Contemporary Approaches;94 7.3.6;VI. Challenges and Issues;97 7.3.6.1;A. Multiple comparisons and type I and type II errors;97 7.3.6.2;B. Genetic heterogeneity;97 7.3.7;Acknowledgments;98 7.3.8;References;98 7.4;Chapter 4: Definition of Phenotype;103 7.4.1;I. Introduction;104 7.4.2;II. Phenotype Choices/Options;106 7.4.2.1;A. Discrete versus continuous traits;106 7.4.2.2;B. Study base differences;106 7.4.2.3;C. Clinical heterogeneity;109 7.4.2.4;D. Endophenotype;115 7.4.2.5;E. Composite phenotype;116 7.4.2.6;F. Narrow versus broad phenotype definition;120 7.4.3;III. Study Design Issues;120 7.4.3.1;A. Measurement error;120 7.4.3.2;B. Misclassification;121 7.4.3.3;C. Loss due to dichotomization/categorization;125 7.4.3.4;D. Effect of narrowing phenotype;126 7.4.3.5;E. Multiple comparisons;127 7.4.4;IV. Discussion;127 7.4.5;Acknowledgments;128 7.4.6;References;128 7.5;Chapter 5: Genotyping Platforms for Mass-Throughput Genotyping with SNPs, Including Human Genome-Wide Scans;135 7.5.1;I. Introduction: Explosive Need for Mass-Throughput Genotyping;136 7.5.2;II. Microsatellites Versus SNPs;138 7.5.2.1;A. Microsatellites;138 7.5.2.2;B. SNPs;139 7.5.2.3;C. SNPs in whole-genome association studies;140 7.5.2.4;D. SNPs in whole-genome linkage scans;141 7.5.3;III. Genotyping Platforms and Goals;143 7.5.3.1;A. Challenges to mass-throughput genotyping;143 7.5.3.2;B. Genome-Wide platforms;145 7.5.3.3;C. Targeted genotyping platforms;151 7.5.4;IV. Selection of Markers and SNPs;154 7.5.4.1;A. Selection of genome-wide platforms;154 7.5.4.2;B. Selection of targeted platforms;158 7.5.5;V. Novel Markers;158 7.5.6;VI. Future Prospects;161 7.5.6.1;A. SNP-typing platforms in the clinic;162 7.5.6.2;B. Integrative array-based genomic analyses;163 7.5.7;VII. Conclusi
ons;163 7.5.8;References;164 7.6;Chapter 6: Genotyping Errors and Their Impact on Genetic Analysis;169 7.6.1;I. Introduction;170 7.6.2;II. Misspecification of Genetic Relationships;171 7.6.2.1;A. Dissociation of marker data from the individual ID;171 7.6.2.2;B. Inaccurate information about familial relations;171 7.6.2.3;C. Errors in data entry;172 7.6.2.4;D. Related families specified as unrelated;172 7.6.3;III. Detection and Correction of Misspecification of Relationships;172 7.6.3.1;A. GRR;172 7.6.3.2;B. ASPEX;175 7.6.3.3;C. Eclipse;175 7.6.4;IV. Genotype Misclassification;175 7.6.4.1;A. Misclassification rates;176 7.6.4.2;B. Mendelian inconsistencies;176 7.6.4.3;C. Unlikely double recombinants;177 7.6.4.4;D. Allele shifting;178 7.6.5;V. Conclusion;179 7.6.6;References;179 8;Part II: Linkage and Association Analysis;181 8.1;Chapter 7: Model-Based Methods for Linkage Analysis;183 8.1.1;I. Introduction;184 8.1.2;II. The Generalized Single Major Locus Model Description;184 8.1.3;III. The Lod Score;185 8.1.3.1;A. Definition;185 8.1.3.2;B. Examples;185 8.1.3.3;C. The LOD score of 3 criterion;188 8.1.3.4;D. Genome-wide significance level;189 8.1.3.5;E. Affected sib pair methods and LOD scores;190 8.1.3.6;F. Maximum LOD score for ASP;191 8.1.3.7;G. Maximum LOD score versus the LOD score;192 8.1.4;IV. The Mod Score Method;193 8.1.5;V. The Lod Score and Meta-Analysis;194 8.1.5.1;A. SML traits;194 8.1.5.2;B. Complex traits;195 8.1.6;VI. Multilocus Models;196 8.1.7;VII. Strengths and Weaknesses of Model-Based Methods;198 8.1.8;VIII. Discussion;198 8.1.9;References;199 8.2;Chapter 8: Contemporary Model-Free Methods for Linkage Analysis;203 8.2.1;I. Introduction;204 8.2.2;II. Identity by Descent and Identity by State;205 8.2.2.1;A. Multipoint IBD;207 8.2.2.2;B. IBD estimation and intermarker linkage disequilibrium;208 8.2.3;III. Relative Pair Linkage Methods;208 8.2.3.1;A. Discordant pairs;210 8.2.3.2;B. Covariates in affected sib pair analyses;211 8.2.3.3;C. Power;214 8.2.4;I
V. Variance Components Linkage Methods;212 8.2.4.1;A. Nonnormality of the trait distribution;213 8.2.4.2;B. Discrete and categorical traits;214 8.2.4.3;C. Power;214 8.2.5;V. Strengths and Weaknesses of Model-Free Linkage Methods;215 8.2.6;VI. Conclusion;217 8.2.7;Acknowledgments;217 8.2.8;References;217 8.3;Chapter 9: DNA Sequence-Based Phenotypic Association Analysis;223 8.3.1;I. Introduction;224 8.3.1.1;A. DNA sequencing and association studies;226 8.3.1.2;B. Potential analysis methods;227 8.3.2;II. Multivariate Distance Matrix Regression;230 8.3.2.1;A. Computing a distance matrix;230 8.3.2.2;B. MDMR analysis;232 8.3.2.3;C. Assessing significance of the F statistic;233 8.3.2.4;D. Graphical display of distance/similarity matrices;234 8.3.3;III. Simulation Studies;234 8.3.3.1;A. The determination of critical values;235 8.3.3.2;B. The assessment of the power of MDMR;235 8.3.4;IV. Results;237 8.3.4.1;A. The determination of critical values;237 8.3.4.2;B. The assessment of the power of MDMR: Equal effect sizes ;239 8.3.4.3;C. The assessment of the power of MDMR: Diminishing effect sizes;241 8.3.4.4;D. The assessment of the power of MDMR: The influence of neutral loci;241 8.3.5;V. Discussion;241 8.3.6;Acknowledgments;243 8.3.7;References;243 8.4;Chapter 10: Family-Based Methods for Linkage and Association Analysis;247 8.4.1;I. Introduction;248 8.4.1.1;A. Hypothesis testing in family designs;248 8.4.1.2;B. The TDT test for trios;250 8.4.1.3;C. Extensions to the TDT;251 8.4.1.4;D. Design issues;252 8.4.2;II. Analysis Methods: FBAT and PBAT;256 8.4.2.1;A. General test statistic;258 8.4.2.2;B. Coding the genotype;258 8.4.2.3;C. Coding the trait: Dichotomous outcomes;259 8.4.2.4;D. The test statistic: Large sample distribution under the null;259 8.4.2.5;E. The TDT and chi2FBAT;260 8.4.2.6;F. Computing the distribution with general pedigrees and/or missing founders;261 8.4.2.7;G. Haplotypes and multiple markers;262 8.4.2.8;H. Coding the trait for complex phenotypes: Age-to-on
set phenotypes, quantitative outcomes, and FBAT-GEE;264 8.4.2.9;I. A General approach to complex phenotypes: Separating the population and family information in family data;266 8.4.2.10;J. Testing strategies for large-scale association studies;268 8.4.3;III. Other Approaches to Family-Based Analyses, Including the PDT and the QTDT;268 8.4.3.1;A. The PDT and APL;272 8.4.3.2;B. Quantitative traits: The QTDT;273 8.4.4;IV. Software;274 8.4.5;V. Discussion;274 8.4.6;References;276 8.5;Chapter 11: Searching for Additional Disease Loci in a Genomic Region;281 8.5.1;I. Introduction;282 8.5.1.1;A. Background;282 8.5.1.2;B. Primary disease genes;285 8.5.1.3;C. Additional (secondary) disease genes in a genetic region;286 8.5.2;II. Primary Disease-Predisposing Genes and Their Genetic Features;289 8.5.2.1;A. Background;289 8.5.2.2;B. Linkage and association tests;290 8.5.2.3;C. Modes of inheritance (recessive versus additive models);292 8.5.2.4;D. The patient/control ratio;295 8.5.2.5;E. Relative predispositional effects;296 8.5.3;III. Detecting Additional Genes in a Genetic Region;299 8.5.3.1;A. Background;299 8.5.3.2;B. Linkage analyses of two linked disease susceptibility genes;299 8.5.3.3;C. Linkage disequilibrium of markers with primary disease genes;300 8.5.3.4;D. Matched cases and controls;301 8.5.3.5;E. Homozygous parent linkage and TDT methods;302 8.5.3.6;F. Conditional haplotype methods;303 8.5.3.7;G. Conditional genotype methods;307 8.5.3.8;I. Combining association and IBD values;309 8.5.4;IV. Discussion;311 8.5.5;Acknowledgments;313 8.5.6;References;313 8.6;Chapter 12: Methods for Handling Multiple Testing;321 8.6.1;I.Introduction;322 8.6.2;II. Types of Errors in Hypothesis Testing (Type I and Type II);324 8.6.3;III. Striking a Balance Between False Positives and False Negatives;326 8.6.4;IV. Alternative Adjustment Methods;327 8.6.4.1;A. The Bonferroni correction;327 8.6.4.2;B. Permutation testing;328 8.6.4.3;C. False discovery rate;329 8.6.4.4;D. Sequential methods;
330 8.6.4.5;E. Other methods;332 8.6.5;V. Conclusion;333 8.6.6;Acknowledgments;333 8.6.7;References;333 9;Part III: Special Topics;337 9.1;Chapter 13: Meta-Analysis Methods;339 9.1.1;I. Introduction;340 9.1.2;II. Meta-Analysis of Population-Based Association Studies;341 9.1.2.1;A. Background considerations;341 9.1.2.2;B. Special issues in genetic applications;346 9.1.3;III. Meta-Analysis of Linkage Studies;347 9.1.3.1;A. Meta-analysis of significance levels;348 9.1.3.2;B. Parametric meta-analysis for linkage studies;350 9.1.3.3;C. Meta-analysis of genome scans;350 9.1.4;IV. Special Issues;352 9.1.4.1;A. Nonreplication of early genetic claims;352 9.1.4.2;B. Biases in meta-analyses, with emphasis on genetic meta-analysis;354 9.1.4.3;C. Meta-analyses of individual participant data and consortia of investigators;355 9.1.4.4;D. Meta-analysis of genome-wide association studies;355 9.1.4.5;E. Meta-analysis of gene-gene-environment data;356 9.1.5;References;357 9.2;Chapter 14: Haplotype-Association Analysis;363 9.2.1;I. Introduction;364 9.2.2;II. Haplotype Inference From Unrelated Individuals;365 9.2.2.1;A. Statistical methods;366 9.2.2.2;B. Combinatorial algorithms;370 9.2.2.3;C. Some extensions and other methods;373 9.2.3;III. Haplotype Inference From Pedigrees;377 9.2.3.1;A. Brief introduction for haplotype inference using pedigrees;377 9.2.3.2;B. Rule-based methods for haplotype inference using pedigrees;378 9.2.3.3;C. Likelihood-based methods for haplotype inference using pedigrees;383 9.2.3.4;D. The program packages;390 9.2.4;IV. Population-Based Haplotype-Association Methods;390 9.2.4.1;A. Score statistics for haplotype analysis;390 9.2.4.2;B. Haplotype-association analysis using regression models;395 9.2.5;V. Family-Based Association Methods Using Haplotypes;404 9.2.5.1;A. Brief introduction;404 9.2.5.2;B. Family-based association methods using single markers;405 9.2.5.3;C. Methods for phase known data;407 9.2.5.4;D. Methods for phase unknown data;410 9.2.5.5;E. The
program packages;419 9.2.6;VI. Discussion;419 9.2.7;Acknowledgments;421 9.2.8;References;421 9.3;Chapter 15: Characterization of LD Structures and the Utility of HapMap in Genetic Association Studies;435 9.3.1;I. Introduction;436 9.3.2;II. Haplotype Similarity in Candidate Genes and LD Mapping;437 9.3.2.1;A. Founder heterogeneity;438 9.3.2.2;B. Multiple candidate genes and global test;439 9.3.2.3;C. Other practical issues;441 9.3.3;III. Global Organization of LD Structures;442 9.3.3.1;A. HapMap and tagSNPs;443 9.3.3.2;B. Similarity of HapMaps and transferability of tagSNPs;446 9.3.3.3;C. Implications to GWA;446 9.3.4;IV. Variation of Local LD Structures;448 9.3.4.1;A. The marker ambiguity score method;449 9.3.4.2;B. Implications for GWA studies;451 9.3.5;V. Discussion;453 9.3.6;Acknowledgment;457 9.3.7;References;458 9.4;Chapter 16: Associations Among Multiple Markers and Complex Disease: Models, Algorithms, and Applications;465 9.4.1;I. Introduction;466 9.4.2;II. A Model for "Diplotypes";632 9.4.2.1;A. Independence and the multinomial model;470 9.4.2.2;B. Strand-specific probabilities and resampling;470 9.4.3;III. Strand-Specific Inference in the Absence of Randomness in P;474 9.4.4;IV. Haploview and Our View;632 9.4.4.1;A. Testing: Individual pairs of alleles and omnibus tests;476 9.4.4.2;B. Clustering;480 9.4.5;V. Approaches to Two-Class Association/Classification;482 9.4.6;VI. Restrictions on Probabilities Entailed by Hardy-Weinberg Equilibrium;487 9.4.7;VII. Discussion and Summary;488 9.4.8;Acknowledgments;490 9.4.9;References;490 9.5;Chapter 17: Study Designs for Genome-Wide Association Studies;493 9.5.1;I. Introduction;494 9.5.2;II. Basic Principles of Association Design;499 9.5.2.1;A. Retrospective case-control studies;500 9.5.2.2;B. Prospective cohort and nested case-control studies;504 9.5.2.3;C. Continuous phenotypes;505 9.5.2.4;D. Using genome-wide SNP data to adjust for population stratification and other biases;506 9.5.2.5;E. Family-based designs;507
9.5.3;III. The Genetic Architecture of Complex Traits;508 9.5.4;IV. Genotyping Technologies;510 9.5.5;V. Power Calculations for Multistage Design;513 9.5.5.1;A. Appropriate significance thresholds for power calculations;513 9.5.5.2;B. Power and cost calculations for multistage designs;515 9.5.6;VI. Discussion;521 9.5.7;References;523 9.6;Chapter 18: Ethical, Legal, and Social Implications of Biobanks for Genetics Research;533 9.6.1;I. Introduction;534 9.6.2;II. Governance of Biobanks;535 9.6.3;III. Risks and Benefits;540 9.6.3.1;A. Individual risks and potential benefits;541 9.6.3.2;B. Societal risks and benefits;542 9.6.4;IV. Recruitment of Vulnerable and Minority Populations;544 9.6.5;V. Informed Consent;546 9.6.5.1;A. Approaches to biobank consents;547 9.6.5.2;B. Tiered consent;548 9.6.5.3;C. General consent;549 9.6.6;VI. Storage of Genetic InformationOptimizing Privacy;550 9.6.7;VII. Biospecimen/Data Access;552 9.6.8;VIII. Ownership and Intellectual Property;553 9.6.9;IX. Disclosure of Research Results;555 9.6.9.1;A. Individual research results;555 9.6.9.2;B. Aggregate research results;562 9.6.10;X. Commercialization of Biobanks;564 9.6.11;XI. Conclusion;566 9.6.12;References;567 10;Part IV: Promising Topics;573 10.1;Chapter 19: Admixture Mapping and the Role of Population Structure for Localizing Disease Genes;575 10.1.1;I. Introduction;576 10.1.2;II. Population Genetic Structure in Humans;577 10.1.3;III. Population Admixture;578 10.1.4;IV. Methods of Admixture Mapping;579 10.1.4.1;A. The basic idea;579 10.1.4.2;B. Test statistics;581 10.1.4.3;C. Inferring locus-specific ancestry;585 10.1.4.4;D. Genome-wide significance level;586 10.1.4.5;E. Software available;588 10.1.5;V. Design Consideration;589 10.1.5.1;A. Markers for admixture mapping;589 10.1.5.2;B. Power and sample size;590 10.1.6;VI. Prospects and Concerns of Admixture Mapping;591 10.1.7;VII. Conclusions;593 10.1.8;Acknowledgment;594 10.1.9;References;594 10.2;Chapter 20: Integrating Global Gene Express
ion Analysis and Genetics;599 10.2.1;I. Introduction;600 10.2.2;II. Technical and Experimental Design Issues for Microarrays;603 10.2.2.1;A. DNA microarray platforms;604 10.2.2.2;B. Microarray data analysis;609 10.2.3;III. Identifying Disease Candidates Using DNA Microarrays;610 10.2.3.1;A. Gene expression catalogs;610 10.2.3.2;B. Differential gene expression in disease;611 10.2.3.3;C. Functional annotation of gene expression patterns;612 10.2.3.4;D. Identification of disease biomarkers;614 10.2.4;IV. Integration of Genetics and Genomics;614 10.2.4.1;A. Mapping gene expression QTL;616 10.2.4.2;B. Prioritizing candidate genes;618 10.2.4.3;C. Modeling causal interactions;620 10.2.4.4;D. Gene coexpression networks;620 10.2.4.5;E. Genetical genomics in human studies;622 10.2.5;V. Conclusions;624 10.2.6;References;625 10.3;Chapter 21: A Systems Biology Approach to Drug Discovery;631 10.3.1;I. Introduction;632 10.3.2;II. Causal Inference: An Integrated Approach to Drug Discovery;634 10.3.3;III. Coexpression Networks;640 10.3.3.1;A. Constructing weighted and unweighted coexpression networks;632 10.3.3.2;B. Using genetics in constructing coexpression networks;642 10.3.3.3;C. Identifying modules of highly interconnected genes in coexpression networks;643 10.3.4;IV. Probabilistic Causal Networks: Bayesian Networks as a Framework for Data Integration;645 10.3.4.1;A. Bayesian networks;646 10.3.4.2;B. Deriving structure priors from genetic data;647 10.3.4.3;C. Structure priors derived from other data sources;650 10.3.5;V. An Insightful Example: Integrating Data Leads to the Identification of Gene Affecting Plasma Cholesterol Levels;653 10.3.6;VI. Conclusions;632 10.3.7;References;658 10.4;Chapter 22: The Promise of Composite Likelihood Methods for Addressing Computationally Intensive Challenges;665 10.4.1;I. Introduction;666 10.4.2;II. Composite Likelihood Methods;666 10.4.3;III. Applications in Population Genetics;669 10.4.4;IV. Applications in Fine Mapping of Disease Mutations
;671 10.4.4.1;A. Terwilliger's method;672 10.4.4.2;B. Devlin et al.'s method;673 10.4.4.3;C. Maleacutecot model for linkage disequilibrium;674 10.4.4.4;D. Other methods;676 10.4.5;V. Other Applications;677 10.4.6;VI. Prospectives and Discussion;678 10.4.7;References;680 10.5;Chapter 23: Comparative Genomics for Detecting Human Disease Genes;683 10.5.1;I. Introduction;684 10.5.2;II. The Power and Promise of Comparative Genomics;687 10.5.2.1;A. Characterization of genes and their regulation;688 10.5.3;III. Animal Models for Human Disease;693 10.5.3.1;A. QTL to gene;694 10.5.3.2;B. Sequence to function;699 10.5.3.3;C. Comparing phenomes;702 10.5.4;IV. Comparative Genomics and Building Better Animal Models;704 10.5.4.1;A. Transgenesis and mutagenesis;704 10.5.4.2;B. Humanizing disease models;706 10.5.4.3;C. Comparative QTL;707 10.5.4.4;D. Genes positionally cloned;708 10.5.5;V. Discussion;709 10.5.6;References;711 11;Part V: Outstanding Challenges;727 11.1;Chapter 24: From Genetics to Mechanism of Disease Liability;729 11.1.1;I. Introduction;730 11.1.2;II. Identification of QTL by Statistical Analysis;731 11.1.2.1;A. QTL mapping in human genetics;731 11.1.2.2;B. Mapping determinants of essential hypertension in humans;731 11.1.2.3;C. The predominant role of the kidney in EH;732 11.1.2.4;D. From QTL to genes in rodents;733 11.1.2.5;E. Few genes, if any, explaining a blood pressure QTL have been identified by the traditional approach;734 11.1.3;III. A Strong QTL For Sodium Sensitivity in the C57BL/6J Mouse Inbred Line;735 11.1.3.1;A. QTL mapping of NaS between C57BL/6J and A/J;735 11.1.3.2;B. Combining data for the chromosome 4 QTL;736 11.1.3.3;C. A QTL that accounts for a small proportion of the total variance of a quantitative phenotype of low specificity, such as BP, may not be amenable to fine mapping and positional cloning;736 11.1.4;IV. From QTL to Genes: Gene Prioritization;741 11.1.4.1;A. Gene prioritization based on differential expression in select tissues or ce
lls;742 11.1.4.2;B. Gene prioritization based on in silico search of functional annotations and genomic differences among strains;744 11.1.5;V. From QTL to Genes: High-Throughput Functional Screens;749 11.1.5.1;A. The ultimate need for a functional proof;749 11.1.5.2;B. The power of high-throughput functional screens;749 11.1.5.3;C. Functional analysis of sodium transport in epithelial cells of the kidney;750 11.1.6;VI. Perspective;751 11.1.7;References;751 11.2;Chapter 25: Into the Post-HapMap Era;755 11.2.1;I. Introduction;756 11.2.2;II. Linkage Mapping and Cytogenetic Assignment;757 11.2.3;III. Association Mapping and Functional Assignment;758 11.2.4;IV. Fully Parametric Analysis;760 11.2.5;V. Meta-Analysis;760 11.2.6;VI. Analysis of msSNPs;761 11.2.7;VII. The False Discovery Rate;762 11.2.8;VIII. Early-HapMap Projects;763 11.2.9;IX. Genome-Wide Association Scans;765 11.2.10;X. What Next?;766 11.2.11;References;768 12;Index;771